Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of Translational Science, will present at the Thirteenth London International Cough Symposium taking place July 18 – 19, 2024 at Imperial College in London, U.K.
In his presentation, scheduled for 12:00 CEST / 11:00 BST, on Friday, July 19, 2024, in the Huxley Building, Imperial College London, Dr Kalinichev will discuss the antitussive activity of a novel GABAB receptor-positive allosteric modulator in preclinical-models-of chronic cough.
About GABAB activation and cough
The main inhibitory neurotransmitter GABA activates ionotropic (GABAA) and metabotropic (GABAB) types of receptors. GABAB receptors are widely expressed on airways and in the central and peripheral components of the cough neural circuit. Activating GABAB receptors to treat chronic cough has been clinically validated with baclofen, a selective GABAB agonist, that binds the receptor within the orthosteric GABA binding site. Baclofen is used off-label to treat chronic cough patients, but its wider use is limited due to side effects, short half-life and gradual loss of efficacy during chronic treatment. Targeting an allosteric binding site of the GABAB receptor is expected to provide many advantages, including higher selectivity, better tolerability and lack of tolerance compared to orthosteric compounds.
